Related Experiment Video
Updated: Mar 12, 2026
Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
Published on: September 3, 2021
Bevacizumab Associated with Chemotherapy for Initially Non-resectable Liver Metastases from Colorectal Cancer: a
Marie Alt1, Stéphanie Truant2, Thibaut Renaud-Vantroys1
1Department of Medical Oncology, University Hospital, Lille, France.
Background:
The place of bevacizumab in therapy of patients with initially non-resectable liver metastases from colorectal cancer (CRC) remains debated. Bevacizumab may increase the efficacy of chemotherapy but it may also maintain dormant micrometastases in a dormant state, eventually increasing the long-term likelihood of tumor relapse. The aim of this study was to explore this hypothesis.
Patients And Methods:
A retrospective case-control study was performed in patients with initially non-resectable CRC liver metastases. Metastases were rendered resectable after chemotherapy with (cases) or without (controls) bevacizumab. Cases and controls were matched for synchronicity, number and maximal size of metastases. The main objective was the disease-free survival (DFS).
Results:
A total of 82 patients were enrolled (41 in each group). The median DFS was 12.0 months in the bevacizumab group, and 10.2 months in the group treated with chemotherapy alone (p=0.26).
Conclusion:
We observed no significant effect on DFS for bevacizumab when added to chemotherapy in patients with initially non-resectable liver metastases. Prospective trials on this issue are warranted.
More Related Videos
04:22Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014